From: Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
Parameter | Mean value | Data distribution | Reference |
---|---|---|---|
Population distribution | No variation | [31] | |
50 – 64 years | 5′963,690 | ||
65 – 74 years | 1′987,534 | ||
75 – 79 years | 641,029 | ||
80 – 99 years | 630,983 | ||
Discount rate | 3% | No variation | Assumption |
Vaccination coverage | 70% | Beta | Assumption |
Epidemiological parameters: | |||
Incidence of bacteremia: | Beta | [24] | |
50-64 years | 0.0667% | ||
≥ 65 years | 0.181% | ||
Incidence of meningitis: | Beta | ||
50-64 years | 0.0046% | ||
≥ 65 years | 0.0114% | ||
Incidence of all-cause pneumonia: | Beta | ||
50-64 years | 0.3281% | ||
≥ 65 years | 2.1627% | ||
Bacteremia mortality: | Beta | ||
50 – 64 years | 3.5% | ||
65 – 74 years | 5.7% | ||
75 – 84 years | 11.4% | ||
85 – 99 years | 27.5% | ||
Meningitis mortality: | Beta | ||
50 – 64 years | 26.7% | ||
65 – 74 years | 19.5% | ||
75 – 84 years | 37.4% | ||
85 – 99 years | 40.0% | ||
Inpatient pneumonia mortality: | Beta | ||
50 – 64 years | 0.9% | ||
65 – 74 years | 2.9% | ||
75 – 84 years | 6.2% | ||
85 – 99 years | 14.6% | ||
Costs (U.S. $) | |||
Inpatient pneumonia | Mean (SD) | ||
50 – 64 years | 1,765 (4,005) | Gamma | Sura EPS (local data) |
65 – 74 years | 1,932 (4,721) | ||
75 – 79 years | 2,688 (12,332) | ||
80 – 99 years | 1,309 (3,355) | ||
Bacteremia | |||
50 – 64 years | 10,434 (16,835) | Gamma | Sura EPS (local data) |
65 – 74 years | 8,495 (10,782) | ||
75 – 79 years | 6,753 (10,380) | ||
80 – 99 years | 4,849 (9,772) | ||
Meningitis | |||
50 – 64 years | 7,789 (8,114) | Gamma | Sura EPS (local data) |
65 – 74 years | 7,783 (8,025) | ||
75 – 79 years | 7,783 (8,025) | ||
80 – 99 years | 7,783 (8,025) |